After DEX intervention, the level of 5-HT increased with a decrease in 5-HT1AR and ameliorated attention deficit and hyperactive behaviors, suggesting that the GR agonist or 5-HT1AR inhibitor may serve as a potential target for the treatment of ADHD. Here, HTR5A is linked to attention deficit-hyperactivity disorder.